Core Viewpoint - The domestic medical beauty industry is facing significant scrutiny due to allegations regarding the quality and labeling of collagen products, particularly targeting the leading company, Giant Bio, and its flagship product, "Collagen Stick" [1][5][6]. Industry Overview - The controversy highlights the lack of national standards for the testing of recombinant collagen in cosmetics, leading to significant discrepancies in test results as companies rely on self-defined methods or pharmaceutical industry standards [5][6]. - The National Medical Products Administration has initiated the establishment of industry standards for recombinant collagen and its testing methods, with companies participating in the process [5]. Company-Specific Issues - Giant Bio's "Collagen Stick" was accused of having a collagen content of only 0.0177%, which is below the national cosmetic labeling requirement of 0.1% for non-trace additives, and the key amino acid glycine was reportedly not detected [6][8]. - In response to the allegations, Giant Bio issued a statement denying the claims, asserting that their products meet the required standards and have been approved by regulatory authorities [8]. Testing Method Discrepancies - The testing methods used by the parties involved differ significantly; the blogger employed a high-precision HPLC method, while Giant Bio referenced outdated national standards that have been criticized for their ineffectiveness in the current complex cosmetic landscape [9][10]. - The HPLC method is noted for its high sensitivity and ability to accurately quantify amino acids, while the methods referenced by Giant Bio have been deemed inadequate for testing collagen in cosmetics [10][15]. Market Impact - Following the allegations, Giant Bio's stock price fell over 8% on the Hong Kong Stock Exchange, closing down 4.04%, reflecting market concerns over the credibility of its products [8].
可复美产品含量遭质疑,胶原蛋白龙头巨子生物陷“造假”危机